Initiation of Statin therapy: Are there age limits?

Dipan A. Desai, Sammy Zakaria, Pamela Ouyang

Research output: Contribution to journalArticle

Abstract

Cardiovascular disease (CVD) is the leading cause of death, with a higher prevalence in older adults who form an increasing proportion of the population of the United States. Statin treatment reduces cardiovascular morbidity and mortality in middle-aged adults. However, few studies have included older individuals, particularly ages 80 years or older. We review recent publications regarding primary and secondary prevention of CVD with statin therapy in older adults. Risk scores and their limitations in this population are discussed. The association of adverse effects with intensive doses of statin and their interactions with other drugs may be more problematic in older adults. Statin therapy appears cost-effective for individuals with higher CVD risk but this is dependent on the assumptions used. Evidence remains limited regarding the overall benefit of starting statin therapy in adults ages 80 years and older; thus, clinical judgment remains necessary in making this decision.

Original languageEnglish (US)
Pages (from-to)17-25
Number of pages9
JournalCurrent Atherosclerosis Reports
Volume14
Issue number1
DOIs
StatePublished - Feb 2012

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cardiovascular Diseases
Therapeutics
Primary Prevention
Secondary Prevention
Population
Cause of Death
Decision Making
Morbidity
Costs and Cost Analysis
Mortality
Pharmaceutical Preparations

Keywords

  • Cardiovascular disease
  • Cost effectiveness
  • Elderly
  • HMG-CoA reductase inhibitor
  • Polypharmacy
  • Primary prevention
  • Statin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Initiation of Statin therapy : Are there age limits? / Desai, Dipan A.; Zakaria, Sammy; Ouyang, Pamela.

In: Current Atherosclerosis Reports, Vol. 14, No. 1, 02.2012, p. 17-25.

Research output: Contribution to journalArticle

@article{460d2c37808947a6b6833b35a8748e94,
title = "Initiation of Statin therapy: Are there age limits?",
abstract = "Cardiovascular disease (CVD) is the leading cause of death, with a higher prevalence in older adults who form an increasing proportion of the population of the United States. Statin treatment reduces cardiovascular morbidity and mortality in middle-aged adults. However, few studies have included older individuals, particularly ages 80 years or older. We review recent publications regarding primary and secondary prevention of CVD with statin therapy in older adults. Risk scores and their limitations in this population are discussed. The association of adverse effects with intensive doses of statin and their interactions with other drugs may be more problematic in older adults. Statin therapy appears cost-effective for individuals with higher CVD risk but this is dependent on the assumptions used. Evidence remains limited regarding the overall benefit of starting statin therapy in adults ages 80 years and older; thus, clinical judgment remains necessary in making this decision.",
keywords = "Cardiovascular disease, Cost effectiveness, Elderly, HMG-CoA reductase inhibitor, Polypharmacy, Primary prevention, Statin",
author = "Desai, {Dipan A.} and Sammy Zakaria and Pamela Ouyang",
year = "2012",
month = "2",
doi = "10.1007/s11883-011-0220-1",
language = "English (US)",
volume = "14",
pages = "17--25",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Initiation of Statin therapy

T2 - Are there age limits?

AU - Desai, Dipan A.

AU - Zakaria, Sammy

AU - Ouyang, Pamela

PY - 2012/2

Y1 - 2012/2

N2 - Cardiovascular disease (CVD) is the leading cause of death, with a higher prevalence in older adults who form an increasing proportion of the population of the United States. Statin treatment reduces cardiovascular morbidity and mortality in middle-aged adults. However, few studies have included older individuals, particularly ages 80 years or older. We review recent publications regarding primary and secondary prevention of CVD with statin therapy in older adults. Risk scores and their limitations in this population are discussed. The association of adverse effects with intensive doses of statin and their interactions with other drugs may be more problematic in older adults. Statin therapy appears cost-effective for individuals with higher CVD risk but this is dependent on the assumptions used. Evidence remains limited regarding the overall benefit of starting statin therapy in adults ages 80 years and older; thus, clinical judgment remains necessary in making this decision.

AB - Cardiovascular disease (CVD) is the leading cause of death, with a higher prevalence in older adults who form an increasing proportion of the population of the United States. Statin treatment reduces cardiovascular morbidity and mortality in middle-aged adults. However, few studies have included older individuals, particularly ages 80 years or older. We review recent publications regarding primary and secondary prevention of CVD with statin therapy in older adults. Risk scores and their limitations in this population are discussed. The association of adverse effects with intensive doses of statin and their interactions with other drugs may be more problematic in older adults. Statin therapy appears cost-effective for individuals with higher CVD risk but this is dependent on the assumptions used. Evidence remains limited regarding the overall benefit of starting statin therapy in adults ages 80 years and older; thus, clinical judgment remains necessary in making this decision.

KW - Cardiovascular disease

KW - Cost effectiveness

KW - Elderly

KW - HMG-CoA reductase inhibitor

KW - Polypharmacy

KW - Primary prevention

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=84857633784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857633784&partnerID=8YFLogxK

U2 - 10.1007/s11883-011-0220-1

DO - 10.1007/s11883-011-0220-1

M3 - Article

C2 - 22086344

AN - SCOPUS:84857633784

VL - 14

SP - 17

EP - 25

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 1

ER -